In a report released today, Emily Bodnar from H.C. Wainwright reiterated a Hold rating on Sana Biotechnology (SANA – Research Report). The company’s shares closed last Friday at $4.04.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, ACELYRIN, INC., and Gracell Biotechnologies. According to TipRanks, Bodnar has an average return of -6.1% and a 31.37% success rate on recommended stocks.
Currently, the analyst consensus on Sana Biotechnology is a Moderate Buy with an average price target of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.01 and a one-year low of $2.75. Currently, Sana Biotechnology has an average volume of 1.34M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sana Biotechnology (SANA) Company Description:
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
Read More on SANA:
- Sana Biotechnology publishes data showing SC291 evaded immune detection
- Sana Biotechnology to Present at November and December 2023 Investor Conferences
- Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
- Sana, Uppsala announce authorization of first-in-human study of UP421
- Sana: FDA clears IND to study SC291 for B-cell mediated autoimmune diseases
